Enovis Corp (ENOV) FinancialsENOVEnovis Corp

Enovis Corporation (ENOV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is International Reconstructive, accounting for 26.9% of total sales, equivalent to $156.71M. Other significant revenue streams include U.S. Reconstructive and U.S. Bracing & Support. Understanding this composition is critical for investors evaluating how ENOV navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Enovis Corporation maintains a gross margin of 54.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.19%, while the net margin is -0.18%. These profitability ratios, combined with a Return on Equity (ROE) of -54.25%, provide a clear picture of how effectively ENOV converts its operational activities into shareholder value.

In the context of the broader market, ENOV competes directly with industry leaders such as AORT and IART. With a market capitalization of $1.10B, it holds a leading position in the sector. When comparing efficiency, ENOV's gross margin of 54.51% stands against AORT's 64.03% and IART's 54.90%. Such benchmarking helps identify whether Enovis Corporation is trading at a premium or discount relative to its financial performance.

Enovis has shown a gross margin of 54.51% in the most recent quarter, indicating solid profitability despite challenges. The company has also reported a forward P/E ratio of 4.64, suggesting that it may be undervalued relative to its future earnings potential.